Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human amnion-derived mesenchymal stem cell injection for knee osteoarthritis
jRCTa030250517Recruiting
- Sponsor
- Kaneka
- Start
- Jun 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of amniotic mesenchymal stem cells in knee osteoarthritis (OA), sponsored by Kaneka. Primary endpoint: Safety (comprehensive assessment). Started Jun 2026; status: recruiting.
02
Drugs
amniotic mesenchymal stem cells
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on jRCTa030250517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTa030250517.